7-Benzylamino-6-chloro-2-piperazino-4-pyrrolidino-pteridine, a potent inhibitor of cAMP-specific phosphodiesterase, enhancing nuclear protein binding to the CRE consensus sequence in human tumour cells

Biochemical Pharmacology

Volumn 63, Issue 4, 2002, Pages 659-668

  Wagner, Barbara ^a   Jakobs, Sandra ^a   Habermeyer, Michael ^a   Hippe, Frankie ^a   Cho Chung, Yoon Sang ^b   Eisenbrand, Gerhard ^a   Marko, Doris ^a  

^a Rheinland Pfälzische Technische Universität Kaiserslautern Landau   (Germany)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

cAMP; cAMP responsive element; DC TA 46; Nuclear protein binding; Phosphodiesterase; PKA

Indexed keywords

7 BENZYLAMINO 6 CHLORO 2 PIPERAZINO 4 PYRROLIDINOPTERIDINE; BUCLADESINE; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP PHOSPHODIESTERASE; ENZYME INHIBITOR; FORSKOLIN; ISOBUTYLMETHYLXANTHINE; PROTEIN SUBUNIT; PTERIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CELL CYCLE G1 PHASE; CELL LEVEL; CONSENSUS SEQUENCE; CONTROLLED STUDY; CYCLIC AMP RESPONSIVE ELEMENT; DOSE TIME EFFECT RELATION; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM;

1-METHYL-3-ISOBUTYLXANTHINE; 3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; BUCLADESINE; CONSENSUS SEQUENCE; CYCLIC AMP; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DNA; HUMANS; ISOENZYMES; NUCLEAR PROTEINS; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PTERIDINES; TUMOR CELLS, CULTURED;

EID: 0037085005     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(01)00893-0     Document Type: Article

References (35)

1. The cAMP response element binding protein synergises with other transcription factors to mediate cAMP responsiveness
2. Cyclic AMP second messenger systems
3. CAMP-dependent protein kinase: Framework for a diverse family of regulatory enzymes
4. Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors
5. Isolation and characterisation of PDE9A, a novel human cGMP-specific phosphodiesterase
6. Isolation and characterisation of PDE8A, a novel human cAMP-specific phosphodiesterase
7. Cloning and characterisation of a novel human phosphodiesterase that hydrolyses both cAMP and cGMP (PDE10A)
8. Identification and characterisation of a novel family of cyclic nucleotide phosphodiesterases
9. Isolation and characterisation of two novel phosphodiesterase PDE11A variants showing unique structure and tissue-specific expression
10. Characterisation and phosphorylation of PDE10A2, a novel alternative splice variant of human phosphodiesterase that hydrolyses cAMP and cGMP
11. Molecular cloning and characterisation of a distinct human phosphodiesterase gene family: PDE11A
12. 3′,5′-Cyclic nucleotide phosphodiesterase in tumour cells as potential target for tumour growth inhibition
13. Induction of apoptosis by an inhibitor of cAMP-specific PDE in malignant murine carcinoma cells overexpressing PDE activity in comparison to their nonmalignant counterparts
14. Signal transduction and gene control: The cAMP pathway
15. Identification of a cyclic-AMP-responsive element within the rat somatostatin gene
16. Mechanism of inhibition of Raf-1 by protein kinase A
17. Inhibition by cAMP of Ras-dependent activation of Raf
18. 3′,5′-Nucleotide phosphodiesterases: Potential targets for anticancer therapy
19. Synthesis of 7-benzylamino-6-chloro-2-piperazino-4-pyrrolidino-pteridine and novel derivatives free of positional isomers. Potent inhibitors of cAMP-specific phosphodiesterase and of malignant tumour cell growth
20. Combined in vitro/in vivo test procedure with human tumour xenografts for new drug development
21. Suppression of c-Jun/AP-1 activation by an inhibitor of tumour promotion in mouse fibroblast cells
22. Site-selective 8-chloroadenosine 3′,5′-cyclic monophosphate inhibits transformation and transforming growth factor alpha production in Ki-ras-transformed rat fibroblasts
23. Measurement of protein using bicinchoninic acid
24. Isolation of a cDNA clone for the type I regulatory subunit of bovine cAMP-dependent protein kinase
25. The molecular cloning of a type II regulatory subunit of the cAMP-dependent protein kinase from rat skeletal muscle and mouse brain
26. Genetic characterisation of a brain-specific form of the type I regulatory subunit of cAMP-dependent protein kinase
27. Molecular cloning, cDNA structure, and regulation of the regulatory subunit of type II cAMP-dependent protein kinase from rat ovarian granulosa cells
28. The regulatory subunit of cAMP-dependent protein kinase as a target for chemotherapy of cancer and other cellular dysfunctional-related diseases
29. Type II protein kinase A up-regulation is sufficient to induce growth inhibition in SK-N-SH human neuroblastoma cells
30. Growth arrest and induction of apoptosis in breast cancer cells by antisense depletion of protein kinase A-RI alpha subunit: P53-independent mechanism of action
31. Intracellular localisation of 7-benzylamino-6-chloro-2-piperazino-4-pyrrolidino-pteridine in membrane structures impedes the inhibition of cytosolic cyclic AMP-specific phosphodiesterase
32. Activation and selective inhibition of a cyclic AMP-specific phosphodiesterase, PDE-4D3
33. Phosphorylation and activation of a cAMP-specific phosphodiesterase by the cAMP-dependent protein kinase. Involvement of serine 54 in the enzyme activation
34. Phosphorylation of the cAMP response element binding protein CREB by cAMP-dependent protein kinase A and glycogen synthase kinase-3 alters DNA-binding affinity, conformation, and increases net charge
35. Phosphorylation of CREB affects its binding to high and low affinity sites: Implications for cAMP induced gene transcription